US-based genetic testing company Myriad Genetics has acquired personal genomics company Gateway Genomics and its SneakPeek Early Gender DNA Test for $67.5m.

If specific revenue, volume synergy, and EBITDA targets are met, then Gateway Genomics has the chance to earn up to an extra $32.5m in cash in 2023 and 2024.

Myriad Genetics said that the acquisition bolsters its portfolio of women’s health products by increasing access to customised genetic tests during the reproductive stage of a women’s life and beyond.

With the SneakPeek test, Myriad Genetics will be able to serve women earlier in their pregnancy, offering data-driven genetic insights through their lifetime with the non-invasive Prequel prenatal screen,  MyRisk Hereditary Cancer Test with RiskScore for all ancestries, and Foresight carrier screen.

Customers who use SneakPeek can also learn about the advantages of other types of genetic testing provided by Myriad Genetics through increased online engagement.

Myriad Genetics president and CEO Paul Diaz said: “Gateway Genomics and the SneakPeek test reinforce our mission to advance health and well-being for all with innovative science-based tests that bring relevant genetic information to consumers and clinicians in a way that is accurate, affordable and easy to use.

“As a trusted lab source for prenatal and hereditary cancer testing, Myriad can now offer a comprehensive suite of women’s health testing solutions before, during, and after pregnancy.”

The SneakPeek Early Gender DNA Test is claimed to be the only at-home test that can identify a baby’s gender at six weeks of pregnancy.

The test kit features a SneakPeek Snap device that is placed on the upper arm to obtain blood samples in 1-4 minutes, Myriad Genetics said. The samples are sent by mail to Gateway Genomics, and emails with the findings can be received as soon as the same day.